Category Archives: News and Events

BriaCell Files Coronavirus Immunotherapy Patent

BERKELEY, Calif., and VANCOUVER, British Columbia, April 14, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or ...

BriaCell to Present Clinical Data at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting May 29

BERKELEY, Calif., and VANCOUVER, British Columbia, March 31, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or ...

BriaCell Continues Clinical Operations Amidst COVID-19 Pandemic

• Phase I/IIa clinical study of BriaCell’s lead candidate, Bria-IMT™, with Incyte Corporation’s immune checkpoint ...

BriaCell to Present Clinical and Immune Activity at AACR Annual Meeting

• Clinical and immune activity of BriaCell’s lead candidate, Bria-IMT™, alone or in combination with ...

BriaCell Announces Grant to Investigator Dr. Saveri Bhattacharya at Sidney Kimmel Cancer Center – Jefferson Health for Phase I/IIa Combination Study of Bria-IMT™

· Grant awarded to Dr. Saveri Bhattacharya, Principal Investigator of the Phase I/IIa combination study ...

BriaCell’s Clinical Data Accepted to be Presented at the Annual Symposium of Society of Surgical Oncology 2020 in Boston

Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination ...

BriaCell Invited to Present at Mount Sinai’s Frontiers in Academic Pathology Symposium at The New York Academy of Medicine

BERKELEY, Calif., and VANCOUVER, British Columbia, January 22, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or ...

BriaCell Provides Update on Remarkable Responder

• Patient initially identified September 19, 2019 as a Remarkable Responder; • Patient has continued ...

BriaCell Outlines New High Responding Patient Group ‘Biomarker’ Based on Cancer Grade

• BriaCell has identified a patient population Biomarker with high rate of clinical benefit from ...

BriaCell Completes Share Consolidation

BERKELEY, Calif., and VANCOUVER, British Columbia, January 2, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or ...